| Updated research nosology for HIV-associated neurocognitive disorders A Antinori, G Arendt, JT Becker, BJ Brew, DA Byrd, M Cherner, DB Clifford, ... Neurology 69 (18), 1789-1799, 2007 | 3195 | 2007 |
| Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis C Bridel, WN Van Wieringen, H Zetterberg, BM Tijms, CE Teunissen, ... JAMA neurology 76 (9), 1035-1048, 2019 | 683 | 2019 |
| Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study M Gisslén, RW Price, U Andreasson, N Norgren, S Nilsson, L Hagberg, ... EBioMedicine 3, 135-140, 2016 | 505 | 2016 |
| Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19 N Kanberg, NJ Ashton, LM Andersson, A Yilmaz, M Lindh, S Nilsson, ... Neurology 95 (12), e1754-e1759, 2020 | 422 | 2020 |
| HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment A Edén, D Fuchs, L Hagberg, S Nilsson, S Spudich, B Svennerholm, ... Journal of Infectious Diseases 202 (12), 1819-1825, 2010 | 365 | 2010 |
| Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load MJ Peluso, F Ferretti, J Peterson, E Lee, D Fuchs, A Boschini, M Gisslén, ... Aids 26 (14), 1765-1774, 2012 | 305 | 2012 |
| The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? M Gisslén, RW Price, S Nilsson BMC infectious diseases 11, 1-4, 2011 | 304 | 2011 |
| HIV-1 infection and cognitive impairment in the cART era: a review J Schouten, P Cinque, M Gisslen, P Reiss, P Portegies Aids 25 (5), 561-575, 2011 | 297 | 2011 |
| Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection L Hagberg, P Cinque, M Gisslen, BJ Brew, S Spudich, A Bestetti, ... AIDS research and therapy 7, 1-12, 2010 | 266 | 2010 |
| Increased brain-predicted aging in treated HIV disease JH Cole, J Underwood, MWA Caan, D De Francesco, RA Van Zoest, ... Neurology 88 (14), 1349-1357, 2017 | 231 | 2017 |
| Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders E Marklund, S Leach, H Axelsson, K Nyström, H Norder, M Bemark, ... PloS one 15 (10), e0241104, 2020 | 222 | 2020 |
| Immune activation of the central nervous system is still present after> 4 years of effective highly active antiretroviral therapy A Edén, RW Price, S Spudich, D Fuchs, L Hagberg, M Gisslén Journal of Infectious Diseases 196 (12), 1779-1783, 2007 | 217 | 2007 |
| Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection MJ Peluso, DJ Meyerhoff, RW Price, J Peterson, E Lee, AC Young, ... The Journal of infectious diseases 207 (11), 1703-1712, 2013 | 199 | 2013 |
| Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe LM Hofstra, N Sauvageot, J Albert, I Alexiev, F Garcia, D Struck, ... Clinical infectious diseases 62 (5), 655-663, 2016 | 191 | 2016 |
| Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden S Spudich, M Gisslen, L Hagberg, E Lee, T Liegler, B Brew, D Fuchs, ... Journal of Infectious Diseases 204 (5), 753-760, 2011 | 182 | 2011 |
| Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation V Dahl, J Peterson, D Fuchs, M Gisslen, S Palmer, RW Price Aids 28 (15), 2251-2258, 2014 | 177 | 2014 |
| Amyloid and tau cerebrospinal fluid biomarkers in HIV infection M Gisslén, J Krut, U Andreasson, K Blennow, P Cinque, BJ Brew, ... BMC neurology 9, 1-13, 2009 | 177 | 2009 |
| Sweden, the first country to achieve the Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO) 90‐90‐90 continuum of HIV care targets M Gisslén, V Svedhem, L Lindborg, L Flamholc, H Norrgren, S Wendahl, ... HIV medicine 18 (4), 305-307, 2017 | 176 | 2017 |
| Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients J Jessen Krut, T Mellberg, RW Price, L Hagberg, D Fuchs, L Rosengren, ... PloS one 9 (2), e88591, 2014 | 175 | 2014 |
| CSF biomarkers in patients with COVID-19 and neurologic symptoms: a case series A Eden, N Kanberg, J Gostner, D Fuchs, L Hagberg, LM Andersson, ... Neurology 96 (2), e294-e300, 2021 | 173 | 2021 |
